loading page

Nano-antibiotics combined with laser irradiation to reduce the development of drug resistance of K. Pneumoniae and accelerate wound healing
  • +5
  • Tiansheng Liu,
  • Guowei Zhong,
  • Dongying Tang,
  • Xu Liu,
  • Xianghua Zhong,
  • Yuejun Yang,
  • Chunyi Tong,
  • Xiaoping Yang
Tiansheng Liu
Hunan Normal University

Corresponding Author:[email protected]

Author Profile
Guowei Zhong
Hunan University
Author Profile
Dongying Tang
Hunan University
Author Profile
Xu Liu
Hunan University of Chinese Medicine
Author Profile
Xianghua Zhong
Hunan Normal University
Author Profile
Yuejun Yang
Hunan Normal University
Author Profile
Chunyi Tong
Hunan University
Author Profile
Xiaoping Yang
Hunan Normal University
Author Profile

Abstract

Bacterial infections, especially infections caused by multi-drug resistant bacteria, pose a serious threat to human health and bring huge challenges to clinical treatment. The excessive use of antibiotics can easily lead to the emergence of bacterial resistance, which severely limits clinical treatment options. There is an urgent need to develop high-efficiency antibacterial materials and treatment strategies to inhibit infections caused by multidrug-resistant bacteria. In this work, a nanocomposite named Ofloxacin@HMPB@HA(OHH NPs) combined with the laser irradiation was used to reduce the development of drug resistance and accelerate wound healing in a model infected by Klebsiella pneumoniae(K.Pneumoniae). In vitro results showed that compared with OHH NPs or NIR laser irradiation alone, this combination strategy can exert a synergistic effect on anti-K.Pneumoniae by destroying cell integrity with generating ROS and reducing ATP, and also inhibit the development of bacterial resistance. Moreover, in vivo experiments have shown that the system effectively promotes wound healing through killing K.Pneumoniae and promoting the formation of new tissues. In summary, these results indicate that OHH NPs show great potential in the clinical application of bacterial infections.
05 Oct 2021Submitted to Biotechnology and Bioengineering
05 Oct 2021Submission Checks Completed
05 Oct 2021Assigned to Editor
10 Oct 2021Reviewer(s) Assigned
24 Jan 2022Review(s) Completed, Editorial Evaluation Pending
24 Jan 2022Editorial Decision: Revise Major
26 Feb 20221st Revision Received
28 Feb 2022Submission Checks Completed
28 Feb 2022Assigned to Editor
06 Mar 2022Review(s) Completed, Editorial Evaluation Pending
06 Mar 2022Editorial Decision: Accept